Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

RMX Acquires China Rights to Novel Antibiotic from LegoChem

publication date: Jan 20, 2017
RMX Biopharma of Shanghai in-licensed China rights to a next-gen oxazolidinone antibiotic from South Korea's LegoChem Biosciences. RMX will develop, manufacture and market LCB01-0371in China. According to LegoChem, LCB01-0371 has shown improved activity over gram-positive super-bacteria that include MRSA, VRE and MDR-TB. The antibiotic is in early clinical trials. Although details of the agreement were not disclosed, RMX will make upfront and milestone payments, plus royalties. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital